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Summary
Introduction: Hispanics are the fastest growing ethnicity of the US population and
the largest subset includes those of Mexican origin. Hispanics, including Mexican
Americans (MAs), consistently report less tobacco exposure than European
Americans (EAs), but limited data are available regarding differences in the clinical
characteristics, severity of airflow obstruction, and functional status between MAs
and EAs with chronic obstructive pulmonary disease (COPD).
Methods: Participants in a community-based study of aging and frailty among MAs
and EAs, San Antonio Longitudinal Study of Aging, underwent spirometry.
Participants with spirometry values consistent with COPD by Global Initiative for
Chronic Obstructive Lung Disease (GOLD) criteria are described here.
Results: Thirty-four percent (248/721) of the participants who underwent spiro-
metry had evidence of GOLD Stages 1–4 COPD. Significantly more MAs with COPD
reported being never smokers compared to EAs with COPD. Among those with COPD
who also smoked, MAs reported significantly less tobacco exposure than EAs (15.7 vs.
32.4 pack-years, respectively), but both groups had surprisingly similar severities of
airflow obstruction. Additionally, MAs had worse functional status and perceived
health than did EAs.
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Conclusions: Despite significantly less exposure to tobacco smoke, MAs with COPD
had a similar degree of obstruction to airflow compared with EAs with COPD.
Healthcare providers should have a high index of suspicion for COPD in MAs who are
exposed to even small amounts of cigarette smoke.
& 2006 Elsevier Ltd. All rights reserved.
Introduction
Chronic obstructive pulmonary disease (COPD)
affects an estimated 20 million Americans and is
the fourth leading cause of death in the US.1,2
According to the 2000 census, there were 35.2
million Hispanics in the US, accounting for 12.5% of
the total population.3 The Hispanic population is
the fastest growing minority population in the US
and increased 61% between 1990 and 2000.3 In
contrast, the total population increased 13% during
the same period. The largest group within the
Hispanic population is of Mexican origin, comprising
approximately 60% (21 million) of this population.4
COPD is the fourth leading cause of death in
Hispanics over the age of 65 years,5 but the eighth
leading cause of death in Hispanics of all ages in
2000.6 Mortality data from the 1999 National
Center for Health Statistics report the age-adjusted
death rates for emphysema as 2.1 per 100,000
among Hispanics vs. 6.8 per 100,000 among non-
Hispanics.7 Two studies also demonstrated lower
mortality rates from COPD for Mexican Americans
(MAs) in Texas8 and for Hispanic Americans in New
Mexico9 than for non-Hispanic white patients.
However, little is known about the misclassification
of COPD and asthma in the adult Hispanic popula-
tion in the US.10
Recent findings suggest a marked variation in the
prevalence, morbidity, and mortality of asthma in
Hispanics in the US as well as suboptimal manage-
ment of the disease in this population.10,11 How-
ever, limited data suggest that asthma may be
underdiagnosed in Hispanics in the US.10 Virtually
no data exist about the clinical course, severity, or
functional impact of COPD among Hispanics. We are
not aware of any studies that have directly
compared the clinical characteristics (e.g., the
severity of airflow obstruction, concomitant co-
morbidities, functional status, and perceived
health) of MAs with COPD to any other ethnicity
with COPD. We undertook this descriptive study of
MA and European American (EA) elders with COPD
(documented by spirometry) to characterize the
similarities and differences in cigarette exposure,
functional status, co-morbidities, severity of ob-
struction, and perceived health between the two
populations.
Methods
Study population and design
The San Antonio Longitudinal Study of Aging
(SALSA) is a community-based study of chronic
disease and functional status in elder MAs and EAs.
The SALSA sample was comprised of a subset of
elderly (age 65–79 years at time of first SALSA
assessment) subjects enrolled in the San Antonio
Heart Study (SAHS), a large prospective cohort
study established in 1979 to investigate differences
in the etiology and incidence of cardiovascular
disease and diabetes mellitus between MAs and
EAs. The details of the sampling strategy and
methods of the SAHS have been published pre-
viously.12,13 SALSA began in 1991 as part of a
National Institute of Aging-funded initiative to
study physical frailty in minority elderly. Data were
collected from April 1992 to June 1996 and
consisted of a home-based assessment (HBA) given
in participants’ homes plus a performance-based
assessment (PBA) given at The University of Texas
Health Science Center at San Antonio (UTHSCSA)
General Clinical Research Center (GCRC). As part of
the PBA, forced vital capacity (FVC) and forced
expiratory volume at 1 s (FEV1) were assessed three
times for each study participant using a Welch-
AllynTM hand-held spirometer (Pneumocheck).14 A
description of demographic variables and socio-
cultural status of the SALSA cohort has been
previously published.15
Analyses presented here focus on the subset of
participants who underwent spirometry testing and
who met the criteria for COPD based on the Global
Initiative for Chronic Obstructive Lung Disease
(GOLD) guidelines (Stages 1–4).16 No bronchodila-
tors were administered during the spirometry
measurements; therefore, only prebronchodilator
values were obtained. However, we used these
spirometry values to categorize the participants by
the severity of their underlying COPD based on
GOLD staging and criteria. Stage 1 (mild) included
participants with a normal FEV1 (X80% predicted),
but a low FEV1/FVC (o 70%). Participants categor-
ized as Stages 2–4 all had a low ratio (FEV1/
FVCo70%). The differences in these three stages
were based on the FEV1 percent predicted:
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participants with Stage 2 (moderate) had an FEV1
50–79% predicted, Stage 3 (severe) had an FEV1
30–49% predicted, and Stage 4 (very severe) had an
FEV1o30% predicted.16 The local Institutional Re-
view Board (IRB) approved the original SALSA study
and informed consent was obtained for each
participant in the study.
Statistical analysis
The descriptive statistics for discrete data were
evaluated with the w2-test. Univariate analyses
were performed to detect differences between MAs
and EAs in demographics, co-morbidities, tobacco
exposure, severity of obstruction by PFTs, func-
tional status, and perceived health. We performed
a generalized linear model analysis to determine
potential factors (e.g. ethnicity) and confounders
(e.g., diabetes and smoking history) that were
associated with FEV1. In this model, the dependent
variable was FEV1 percent predicted and the
independent variables were ethnicity, diabetes,
tobacco exposure (expressed as never smoked [i.e.,
smoked less than 50 cigarettes in entire life], o10
pack-years, or X10 pack-years), and the potential
interactions. To further analyze the differences in
perceived health, we used simple logistic regres-
sion analyses to determine the associations be-
tween the dependent variable of perceived health
status (i.e., excellent, good, fair, or poor) and the
predictor variables of demographic characteristics,
co-morbidities, lung function, and functional sta-
tus. The test for the proportional odds assumption
with w2, multicollinearity diagnosis and model
goodness-of-fit were verified. The multiple logistic
regression models included associated variables
with P-values o0.20 from the result of simple
logistic regression. The final model was determined
by using the backward elimination method. Sum-
marized multiple logistic regression tables included
the odds ratios and 95% confidence intervals and
the P-values. All statistical analyzes were per-
formed with Statistical Analysis System (SAS)
Version 8.2.
Results
Thirty-four percent (248/721) of the participants
on whom spirometry was obtained within the SALSA
cohort had evidence of GOLD Stages 1–4 COPD.16,17
MAs comprised 48% (N ¼ 120) and EAs comprised
the remaining 52% (N ¼ 128) of the participants
with COPD, Stages 1–4 by GOLD criteria (Table 1).17
Most patients (82%) had mild (Stage 1) or moderate
(Stage 2) COPD. Fourteen percent had severe
(Stage 3) and only 4% had very severe (Stage 4)
COPD. There were no significant ethnic differences
in the proportion of participants with COPD by level
of severity (Table 1).
MAs were statistically younger and had a higher
body mass index (BMI) than did EAs (Table 2). There
were no statistically significant ethnic differences
in the proportion male, but fewer MAs compared
with EAs were married. Cardiac co-morbidities
(angina, electrocardiogram evidence of myocardial
infarction, and self-reported physician-diagnosed
heart attack) were not significantly different
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Table 1 GOLD guideline severity stage prevalence by ethnic group.
Category or GOLD
stage
Spirometry values Mexican Americans
(N ¼ 376)
European Americans
(N ¼ 345)
P-value
Normal FEV1X80% 164 (44%) 147 (43%) NS
FEV1/FVCX70%
Possibly restrictive FEV1o80% 92 (24%) 70 (20%) NS
FEV1/FVCX70%
Stage 1 FEV1X80%, 34 (9%) 40 (12%) NS
FEV1/FVCo70%
Stage 2 FEV1 50–79%, 62 (17%) 66 (19%) NS
FEV1/FVCo70%
Stage 3 FEV1 30–49%, 16 (4%) 19 (5%) NS
FEV1/FVCo70%
Stage 4 FEV1o30%, 8 (2%) 3 (1%) NS
FEV1/FVCo70%
GOLD: Global initiative for chronic obstructive lung disease, N: number, FEV1: forced expiratory volume in 1 s (percent of
predicted), FVC: forced vital capacity, NS: not significant.
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between the two groups; however, more MAs than
EAs were diagnosed with diabetes (Table 2).
Significantly more MAs with COPD reported that
they were never smokers compared with the EAs
with COPD (Table 3). Subjects were classified as
‘‘never smokers’’ if they denied smoking at least 50
cigarettes during their entire lifetime. In addition,
the group of MAs who did smoke, had significantly
less tobacco exposure than did EAs, based on MAs
having fewer pack-years (smoking fewer cigarettes
per day for fewer total number of years smoked)
(Table 3). A higher percentage of MA participants in
the COPD cohort (14.2%) were first generation in
the US compared with the MAs in the rest of the
cohort (8.9%). Despite these differences in smoking
exposure and habits, MAs had similar severities of
obstruction to airflow by PFTs to EAs (Table 3). In
our cohort of COPD participants, predictors of
increased severity of FEV1 were MA ethnicity ðP ¼
0:0475Þ and number of pack-years of exposure to
cigarette smoke (with higher exposure associated
with lower FEV1 percent predicted, P ¼ 0:0405).
Other variables tested and not found to be
significant predictors were diabetes and cardiovas-
cular disease. Age, height, and gender were not
included in the model because these variables are
used to determine the predicted values of FEV1.
Functional status and perceived health were worse
for the MAs compared with the EAs. Over two-thirds
(69%) of the MAs with COPD were either unable to
perform the 6-min walk test or were able to walk only
the shortest distance measured vs. just over half
(52%) of the EAs (Table 3). In addition, fewer MAs
rated their overall perceived health as ‘‘excellent’’
and significantly more of them reported ‘‘fair or
poor’’ health compared with the EAs (Table 3).
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Table 2 Demographics and characteristics of SALSA Cohort with COPD by spirometry: Stages 1–4 COPD.
Mexican Americans
(N ¼ 120)
European Americans
(N ¼ 128)
P-value
Mean age (years) (SD) 68.7 (3.1) 70.0 (3.5) 0.002
Male (%) 43 53 NS (0.12)
Mean BMI (SD) 28.5 (5.5) 27.0 (4.9) 0.024
BMI430, N (%) 36 (30) 30 (24) NS (0.25)
Married (%) 57 76 0.002
Diabetes (%) 23 9 o 0.01
Asthma (%) 3 2 NS (1.00)
Heart attack (%) 12 16 NS (0.37)
SD: standard deviation, NS: not significant, BMI: body mass index.
Table 3 Univariate analysis of characteristics of Mexican Americans and European Americans within SALSA
Cohort with Stages 1–4 COPD.
Mexican Americans
(N ¼ 120)
European Americans
(N ¼ 128)
P-value
Never smokers (%) 43 26 0.005
Mean # cigarettes/day (SD)y 9.3 (14.3) 18.5 (17.4) 0.03
Mean # years smoked (SD)y 16.1 (20.3) 25.4 (21.1) 0.06
Mean # pack-years 15.7 (28.8) 32.4 (35.4) o0.0001
FEV1 % predicted (SD) 68.3 (23.0) 70.5 (20.5) NS (0.438)
6 MWT (shortest or unable) (%) 69 52 o 0.01
Perceived health (%)
Excellent 20 35
Good 49 51
Poor/fair 31 14 o 0.01
N and #: number, SD: standard deviation, 6 MWT: 6min walk test, FEV1: forced expiratory volume in 1 s.
Answered ‘‘No’’ to question ‘‘Have you ever smoked at least 50 cigarettes in your entire life?’’.
yAnalysis included only participants with smoking history of450 cigarettes in their lifetime.
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Discussion
MAs with COPD reported less exposure to tobacco
smoke (fewer pack-years) than did EAs with COPD,
but both groups had surprisingly similar severities
of airflow obstruction. Additionally, our cohort of
MAs had worse functional status and perceived
health than did the EAs in the cohort. Possible
explanations for the findings of similar COPD
severity, despite lower levels of tobacco exposure
in the MA participants include: (1) a systematic bias
in reporting tobacco exposure; (2) underlying
genetic differences that may predispose MAs to
lung damage with smoke exposure; and/or (3)
ethnic differences in occupational or other toxic
exposures (e.g., exposure to passive smoke or
wood-burning stoves).
The first possibility for our findings involves the
introduction of a systematic bias due to under-
reporting of tobacco use in MAs. Our results are
consistent with other studies demonstrating less
exposure to tobacco in Hispanics than in other
ethnic groups.18–21 The 1997 National Health Inter-
view Survey data, for example, showed that the
current smoking prevalence among Hispanic adults
was 20.4% compared with 25.3% for non-Hispanic
whites.18 This survey demonstrated that Hispanics
smoked fewer cigarettes per day and were more
likely to smoke only occasionally (less than daily)
compared to non-Hispanic white smokers. National
surveys relied on anonymous self-reporting and also
demonstrated lower tobacco exposure in MAs than in
EAs.18,19 However, two studies evaluated the validity
of self-reported smoking status in Hispanics by
measuring cotinine levels and correlating these
levels with self-reports of tobacco exposure from
the Third National Health and Examination Survey
(NHANES-III).20,21 These two studies demonstrated
that Hispanics overall had lower cotinine levels than
other ethnic groups, confirming that Hispanics had
less exposure to tobacco. In addition, one of these
studies showed that the highest degree of correla-
tion between self-reports of smoking exposure and
cotinine levels was in Hispanics, suggesting that
their self-reported exposure history was the most
reliable.21 Therefore, the significantly lower reports
of exposure to tobacco in our cohort of MAs with
COPD were consistent with other studies in the
literature and were likely true differences, rather
than the result of underreporting.
The second possibility that must be considered to
account for similar degrees of airflow obstruction,
despite less tobacco exposure in MAs, is underlying
genetic differences. Other than the discovery of
alpha-1-antitrypsin deficiency as a specific genetic
defect leading to early onset COPD, the field of the
genetics of COPD is in its infancy.22 Japanese
scientists have reported a relationship between
genetic variation in beta-defensin-1 and develop-
ment of COPD after exposure to cigarette smoke.23
However, there is a lack of basic epidemiological,
family, and genetic studies in MAs with COPD.
The third possible explanation for our finding of
similar severity despite lower tobacco exposure
involves differential levels of occupational and/or
environmental exposure to toxins, which were not
captured by our questionnaires or interviews. In a
previous analysis of the NHANES III data, MAs with
COPD were found to have the highest association
between airflow obstruction and industry/occupa-
tion exposure (particularly agriculture) of the
ethnic groups studied.20 In addition, other differ-
ences in toxic exposure are possible. More MAs with
COPD in our study were first generation from
Mexico compared with the remaining MAs in the
SALSA cohort without COPD. These particular
participants who were first generation from Mex-
ico, may have been exposed to wood-burning stoves
with poor to no ventilation and/or to agricultural
occupations.24–28 All of these environmental ex-
posures likely increase the risk for COPD in MAs,
even without tobacco exposure. The explanation of
the lower observed COPD mortality in Hispanics
with COPD could be entirely due to lower COPD
incidence in Hispanics due to lower tobacco
exposure or it could be due to a milder severity
of disease once acquired or both.
The importance of our findings lies in their public
health implications. MAs and their healthcare
providers cannot be reassured by the fact that
MAs smoke less than EAs when the consequences of
any smoking may be worse for MAs than for EAs. In
fact, Hispanics are less likely to receive smoking
cessation advice from healthcare providers than is
the general population.19 The CDC recently re-
ported that in the Youth Risk Behavior Survey, past-
month smoking increased among African American
students by 80% and among Hispanic students by
34% from 1991 through 1997.19 More specifically,
past-month smoking prevalence increased from 13%
to 23% among African Americans and from 25% to
34% among Hispanics. Our data suggest that
healthcare providers should likely have a high
clinical suspicion for COPD in MAs who smoke,
even with a relatively small amount of tobacco
exposure.
There were limitations to our study that must be
considered. First, the spirometry values were
obtained without the administration of any bronch-
odilators (i.e., pre-bronchodilator values). Because
the GOLD criteria define the stages of severity
based on post-bronchodilator spirometry values,
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some of the participants in our study may have
been misclassified with more severe disease than
they actually had. However, it is unlikely that the
bronchodilator response of MAs in our study
differed significantly from that of EAs. Another
limitation is that the data were collected from 1992
to 1996, which may not accurately represent a
similar population today particularly since the
prevalence of COPD continues to increase.29 An-
other limitation of our study is that specific data
were not collected regarding exposure to occupa-
tional and/or environmental toxins that could be
particularly important in MAs with COPD and could
possibly explain our findings. Future research on
the prevalence, incidence, and course of COPD in
MAs should include a detailed exposure history to
help determine the extent to which occupational
and environmental toxins contribute to airflow
obstruction in MAs with COPD. Additional data
need also be obtained on family histories of COPD
with the aim of identifying potential family
clustering of COPD occurrence with minimal tobac-
co exposure. Finally, there is a possibility of
prevalence bias among these subjects with COPD,
in that the most severe cases may have died. This
may result in an upward bias for MAs if the
mortality rate for EAs is truly higher than the
mortality rate for MAs with COPD.
Conclusions
Our findings of similar severities of lung dysfunction
in MAs with COPD, despite significantly lower
tobacco exposure than in EAs, should prompt
healthcare providers to have a higher suspicion
for COPD in MAs who smoke. As with other ethnic
groups, healthcare providers should aggressively
recommend smoking cessation for MAs. The Sur-
geon General has already identified the need for
future research, which should focus on how tobacco
use affects coronary heart disease, stroke, cancer,
chronic obstructive pulmonary disease, and other
respiratory diseases among members of racial/
ethnic groups.19 Our study underscores further
how important this is. Finally, collecting a complete
occupational/environmental exposure history and
family history may be of particular importance in
the Mexican American population.
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